AI assistant
Sending…
Lineage Cell Therapeutics Inc. — Proxy Solicitation & Information Statement 2026
Apr 30, 2026
6895_rns_2026-04-30_f0647354-d2a8-4ba9-af48-a15e95233dca.htm
Proxy Solicitation & Information Statement
Open in viewerOpens in your device viewer
Official notification to shareholders of matters to be brought to a vote ("Proxy") false
| ליניאג' סל תרפיוטיקס אינק | 2 380 |
| .LINEAGE CELL THERAPEUTICS, INC | |
| Corporation no: 876343 | 10834 |
| - - - | |
| Israel Securities Authority | Tel Aviv Stock Exchange | C002 ( Public ) | Reported via MAGNA: | 30/04/2026 | ||||||
| www.isa.gov.il | www.tase.co.il | Reference: | 2026-02-039916 | Time of broadcast: 12:02 12:02 |
Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000
| The corporation is a foreign private issuer as defined by U.S. Securities Laws. |
Attached hereto is a report onOfficial notification to shareholders of matters to be brought to a vote ("Proxy")
First_Form_isa.pdf
| References of previous documents relating to this matter(the reference does not constitute incorporation by reference): | |
| - - - | |
| Stock Exchange/Market: -1 | Date of revision of form structure: 06/08/2024 |
| Address: HARBOR BAY PARKWAY 1301 , ALAMEDA 94502 CALIFORNIA , U.S.A Tel: 5105213390 , Fax: 5105213389 | |
| E-mail address: [email protected] Company site: biotimeinc.com | |
| Previous names of reporting entity: .BIOTIME, INC | |
| Name of the Signatory: Gerzi SHNEOR Ilan Position of Signatory in the reporting corporation: Legal Adviser Name of Employer Company: PEARL COHEN ZEDEK LATZER BARATZ | |
| Address: Derech Menachem Begin 121 , Tel Aviv 6701203 Telephone: 03-3039000 Facsimile: E-mail: [email protected] 1 | |
| U.S.A |
More from Lineage Cell Therapeutics Inc.
Report Publication Announcement
2026
May 13
Interim / Quarterly Report
2026
May 13
Earnings Release
2026
May 13
Report Publication Announcement
2026
May 13
Report Publication Announcement
2026
May 13
Interim / Quarterly Report
2026
May 12
Regulatory Filings
2026
May 12
Report Publication Announcement
2026
May 5
Earnings Release
2026
May 5
Investor Presentation
2026
May 4